Ada Health Patient Finder Partnership Evaluation | March 2026
Analysis Date: March 11, 2026
Analyst: Ada Cockpit Research
Company: Ipsen S.A. (€3.68B FY 2025 Revenue)
This analysis evaluates Ipsen's drug portfolio for suitability with Ada Health's Patient Finder product, which finds undiagnosed patients via symptom assessment and navigates them to care (revenue model: 8-12% of first-year drug revenue per patient found).
| Drug | Indication | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (5% Capture) |
|---|---|---|---|---|---|
| Iqirvo (Elafibranor) | Primary Biliary Cholangitis | 1 | 9/10 | 3,798 | $1,310,000 |
| Somatuline (Lanreotide) | Acromegaly | 1 | 9/10 | 2,844 | $780,000 |
| Dysport (AbobotulinumtoxinA) | Cervical Dystonia | 1 | 8/10 | 6,000-9,000 | $217,000-$324,000 |
| Somatuline (Lanreotide) | Neuroendocrine Tumors | 2 | 6/10 | Limited | Minimal |
| Cabometyx (Cabozantinib) | RCC, HCC | NO | 2/10 | N/A | N/A |
| Onivyde (Liposomal Irinotecan) | Pancreatic Cancer | NO | 3/10 | N/A | N/A |
| Decapeptyl (Triptorelin) | Prostate Cancer | NO | 2/10 | N/A | N/A |
| Tazverik (Tazemetostat) | Follicular Lymphoma, Epithelioid Sarcoma | NO | 3/10 | N/A | N/A |
| Bylvay (Odevixibat) | PFIC, Alagille Syndrome | NO | 4/10 | N/A | N/A |
| Sohonos (Palovarotene) | Fibrodysplasia Ossificans Progressiva | NO | 5/10 | ~165-330 | Negligible |
Why This Is the #1 Priority:
| Market | Total PBC Patients | Undiagnosed (30%) | UDCA Inadequate (40%) | Ada-Addressable (30%) |
|---|---|---|---|---|
| USA | 105,506 | 31,652 | 12,661 | 3,798 |
| DACH | 41,963 | 12,589 | 5,036 | 1,511 |
| ROW | 100,000 | 30,000 | 12,000 | 3,600 |
| Capture Rate | USA Ada Revenue | Global Ada Revenue |
|---|---|---|
| 1% | $262,000 | $826,000 |
| 5% | $1,310,000 | $4,130,000 |
Invest $2M-$8M annually (10-25% of Iqirvo marketing budget) in patient finding. Expected ROI at 5% capture: $4.13M Ada revenue globally. Position as "market expansion, not marketing budget" narrative. Capture 2026-2028 window before saroglitazar and linerixibat launch.
Why Pursue Despite Generic Competition:
| Market | Total Acromegaly Patients | Undiagnosed (35%) | Somatuline-Eligible (65%) | Ada-Addressable (50%) |
|---|---|---|---|---|
| USA | 25,000 | 8,750 | 5,688 | 2,844 |
| DACH | 7,182 | 2,514 | 1,634 | 817 |
| ROW | 14,000 | 4,900 | 3,185 | 1,593 |
| Capture Rate | USA Ada Revenue | Global Ada Revenue |
|---|---|---|
| 1% | $156,000 | $368,000 |
| 5% | $780,000 | $1,840,000 |
Invest $1M-$2M annually (defensive positioning budget) in patient finding. Mature product facing generics, but 8-10 year diagnostic delay justifies investment. Position as differentiation vs. generic "me-too" offerings. Pilot in 1-2 US regions to test defensive strategy effectiveness.
Why Pursue as Strategic Differentiation:
| Market | Total CD Patients | Undiagnosed (25%) | Botulinum Toxin Eligible (80%) | Ada-Addressable (50%) |
|---|---|---|---|---|
| USA | 75,000 | 18,750 | 15,000 | 7,500 |
| DACH (Germany focus) | 21,172 | 5,293 | 4,234 | 2,117 |
| Capture Rate | USA Ada Revenue |
|---|---|
| 1% | $48,000 |
| 5% | $270,000 |
Invest $500K-$1M annually (portion of therapeutic marketing budget) in patient finding. Positions Dysport as therapeutic leader vs. aesthetics focus. Aligns with +9.7% segment growth and North America expansion. Lower per-patient lifetime value ($72K-$108K) but larger addressable pool (7,500 US patients).
Fit Score: 6/10 | Limited Addressable Pool
NETs (neuroendocrine tumors) present in two forms:
Rationale for Tier 2: Limited to symptomatic carcinoid syndrome patients. Majority of NET diagnoses are imaging-driven. Small addressable pool within overall NET population. Not prioritized for patient finding investment.
| Drug | Indication | Fit Score | Rationale for NO |
|---|---|---|---|
| Cabometyx | RCC, HCC | 2/10 | Imaging-driven (incidental CT findings in RCC; surveillance ultrasound/AFP in HCC cirrhosis patients). Late symptoms (hematuria, jaundice) occur after diagnosis typically made. |
| Onivyde | Pancreatic Cancer | 3/10 | Late nonspecific symptoms (jaundice, abdominal pain, weight loss). 80% diagnosed beyond operable surgery. Imaging-driven diagnosis (CT, MRCP, endoscopic ultrasound). |
| Decapeptyl | Prostate Cancer | 2/10 | PSA screening pathway. Symptoms (urinary obstruction, bone pain) are late signs of advanced disease. Urology referral pathway established. |
| Tazverik | Follicular Lymphoma, Epithelioid Sarcoma | 3/10 | Requires tissue pathology (lymph node biopsy, flow cytometry, EZH2 mutation testing for FL; soft tissue mass biopsy for ES). Imaging/biopsy-driven diagnosis. |
| Drug | Indication | Prevalence | Fit Score | Rationale for NO |
|---|---|---|---|---|
| Bylvay | PFIC, Alagille Syndrome | 1 in 30,000-100,000 | 4/10 | Pediatric presentation; requires genetic testing (ABCB11, ATP8B1, JAG1, NOTCH2); ultra-rare. Patient pool too small for Patient Finder ROI. |
| Sohonos | Fibrodysplasia Ossificans Progressiva | 1 in 1-2 million (330-660 US patients total) | 5/10 | Ultra-rare; requires ACVR1 genetic testing. Only ~165-330 undiagnosed US patients (50% undiagnosed). Modest commercial performance ($20.8M FY 2024, €206.5M-€281M impairment). |
| Drug | Recommended Annual Investment | Expected Ada Revenue (5% Capture) | Strategic Rationale |
|---|---|---|---|
| Iqirvo (PBC) | $2M-$8M | $4.13M (global) | Growth product, 2026-2028 market expansion window, documented diagnostic gap (12.4% AMA testing rate) |
| Somatuline (Acromegaly) | $1M-$2M | $1.84M (global) | Defensive positioning vs. generics, 8-10 year diagnostic delay, differentiate branded offering |
| Dysport (Cervical Dystonia) | $500K-$1M | $270K (USA) | Strategic differentiation medical vs. aesthetics, growing therapeutic franchise (+9.7% CER) |
Combined 5% Capture Across Three Tier 1 Drugs:
Strategic Fit: All three drugs have documented diagnostic delays (3-10 years), distinctive symptom patterns Ada can surface, and high lifetime values justifying 8-12% Patient Finder fees. Iqirvo represents highest-value opportunity due to growth trajectory, timing, and documented care gap.